Aakash Desai· @ADesaiMD · X·· 17 小时前评分70
正文 · 原文
Krascendo 1 #ESMO26: divarasib vs sotorasib/adagrasib, pretreated KRAS G12C NSCLC
➡️ mPFS 9.8 vs 5.7 mo, HR 0.58
➡️ mOS 17.7 vs 12.0 mo, HR 0.56
➡️ ORR 58 vs 32%
➡️ G3-4 TRAEs 24.6 vs 34.5%; diarrhea 66 vs 38%
Where does first-gen G12C fit?
@LungCancerRx @OncoAlert @oncodaily
18 浏览 · 1 赞 · 1 转发 · 0 回复
会议摘要
Krascendo 3: A randomised, phase III trial in progress of divarasib vs immunotherapy or observation in patients with resected, stage II-IIIB, KRAS G12C+ non-small cell lung cancer
https://esmocongress.esmo.orgKRASCENDO-1
https://esmocongress.esmo.orgKRASCENDO-1
https://esmocongress.esmo.org来源：Aakash Desai · x.com